Clinical Trials Logo

Adenocarcinoma of the Prostate clinical trials

View clinical trials related to Adenocarcinoma of the Prostate.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04909957 Recruiting - Clinical trials for Adenocarcinoma of the Prostate

Prediction of Lymph Node Invasion for Prostate Adenocarcinoma

PRED-NCHIR
Start date: January 1, 2021
Phase:
Study type: Observational

Despite lymph node involvement (LNI) being one of the main prognostic factors in patients with prostate cancer (PCa), pelvic lymph node irradiation remains debated, possibly due to an insufficient selection of patients. Significant advances in LNI risk modelling have been achieved with the addition of visual interpretation of magnetic resonance imaging (MRI) data, but it is likely that quantitative analysis could further improve prediction models. In this study, the investigators aimed to develop and internally validate a novel LNI risk prediction model based on radiomic features extracted from pre-operative multimodal MRI.

NCT ID: NCT04694924 Recruiting - Prostate Cancer Clinical Trials

Prospective Prostate Cancer and Patient-reported Outcomes Registry

Prosquare
Start date: October 1, 2020
Phase:
Study type: Observational [Patient Registry]

This study aims to evaluate the use of a digital solution, integrated into the electronic health record, for prospective and structured reporting of clinical and patient-reported outcomes for patients diagnosed with localized or locally advanced prostate cancer.

NCT ID: NCT04586543 Recruiting - Clinical trials for Metastatic Castration-resistant Prostate Cancer

Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

Start date: May 18, 2020
Phase: Phase 2
Study type: Interventional

The objective of this clinical study is to evaluate the effectiveness and safety of selegiline plus docetaxel therapy compared to the standard of care - docetaxel therapy - among patients diagnosed with metastatic, castrate-resistant prostate adenocarcinoma.

NCT ID: NCT03624660 Recruiting - Clinical trials for Adenocarcinoma of the Prostate

Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer

PR11
Start date: September 24, 2018
Phase: N/A
Study type: Interventional

The purpose of this research study is to determine if dose-escalated proton radiation therapy is a good way to treat high-risk prostate cancer. The study features hypofractionation and a simultaneous integrated boost to the magnetic resonance imaging (MRI) identified intraprostatic tumor (IPT) as a method of dose-escalating radiation therapy. The study will include patients with high-risk prostate cancer who are at the highest risk for recurrence. Radiation therapy will be delivered over the course of 8-9 weeks. Additionally, androgen deprivation therapy (ADT) will be started 8-10 weeks prior to starting radiation and continued for a total of 18 months if the patient decides to receive ADT.

NCT ID: NCT02525068 Recruiting - Clinical trials for Adenocarcinoma of the Prostate

A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC

RE-AKT
Start date: December 2014
Phase: Phase 2
Study type: Interventional

A multicentre prospective, randomised, phase II interventional study in mCRPC patients previously treated with 1‐2 lines of chemotherapy and at least 12 weeks of abiraterone with a safety run‐in and single stage phase II expansion cohort.